Literature DB >> 7677664

Species identification of avian mycoplasmas by polymerase chain reaction and restriction fragment length polymorphism analysis.

H H Fan1, S H Kleven, M W Jackwood, K E Johansson, B Pettersson, S Levisohn.   

Abstract

Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis were used to detect and differentiate four pathogenic species (Mycoplasma gallisepticum, M. iowae, M. meleagridis, and M. synoviae) and ten nonpathogenic species of avian mycoplasma. A sequence of 1026 base pairs within the gene for 16S ribosomal RNA (16S rRNA) from avian mycoplasmas was successfully amplified by PCR with oligonucleotide primers (M16SPCR5' and M16SPCR3') common to all avian mycoplasmas tested. Restriction endonucleases (REs) with unique restriction sites, selected by computer-assisted analysis of known sequences of the amplified segment of avian mycoplasma, were then used to digest the PCR products. After electrophoresis of the resulting RE fragments, the RFLP patterns were compared. Combinations of up to six REs (HpaI, HhaI, HaeIII, HphI, FokI, and NlaIV) produced unique RFLP patterns by which the 14 species of avian mycoplasmas could be differentiated. The newly classified avian species M. imitans was also investigated by this method; M. imitans and M. gallisepticum gave identical RFLP patterns with the REs used in this study. The results obtained by the PCR and RFLP analysis were in agreement with current methods for species identification of avian mycoplasmas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677664

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  1 in total

1.  Evaluation of amplified rDNA restriction analysis (ARDRA) for the identification of Mycoplasma species.

Authors:  Tim Stakenborg; Jo Vicca; Patrick Butaye; Dominiek Maes; Thierry De Baere; Rita Verhelst; Johan Peeters; Aart de Kruif; Freddy Haesebrouck; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2005-06-14       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.